International Journal of Nursing Research
International Journal of Nursing Research. 2026; 8: (6) ; 10.12208/j.ijnr.20260285 .
总浏览量: 165
1 宁夏医科大学护理学院 宁夏银川;
2 宁夏医科大学总医院创伤骨科 宁夏银川;
3 宁夏回族自治区人民医院 宁夏银川;
4 宁夏医科大学总医院护理部 宁夏银川;
*通讯作者： 郭淑萍,单位： 宁夏医科大学总医院护理部 宁夏银川; ；
目的 调查老年脆性骨折患者抗骨质疏松药物治疗现状，并分析其影响因素。方法 采用横断面调查法，便利选取宁夏医科大学总医院骨科病区收治的老年脆性骨折患者为研究对象。采用自设一般资料调查表、骨质疏松症认知量表及自我效能量表进行调查。结果 共计290例老年脆性骨折患者纳入研究，其中女性126例，男性164例。患者平均年龄（64.62±5.26）岁。患者的抗骨质疏松药物治疗率为3.45%。抗骨质疏松药物治疗的关联因素包括吸烟史（OR=0.28，95%CI：0.12~0.62）、个人年收入（OR=1.99，95%CI：1.38~2.88）、既往VTE病史（OR=1.85，95%CI：1.08~3.18）。结论 老年脆性骨折患者抗骨质疏松药物应用严重不足，提高患者用药依从性、强化脆性骨折患者管理是改善抗骨质疏松治疗的重要策略。
Objective To investigate the current status of anti-osteoporosis drug therapy in elderly patients with fragility fractures and analyze its influencing factors. Methods A cross-sectional survey was conducted, conveniently selecting elderly patients with fragility fractures admitted to the Orthopedic Ward of General Hospital of Ningxia Medical University as the study subjects. Self-designed general information questionnaires, osteoporosis prevention and awareness tool, and osteoporosis self-efficacy scale were used for investigation. Results A total of 290 elderly patients with fragility fractures were enrolled in the study, including 126 females and 164 males. The average age of the patients was (64.62±5.26) years. The rate of anti-osteoporosis drug therapy was 3.45%. The associated factors for anti-osteoporosis drug therapy included smoking history (OR=0.28, 95%CI:0.12–0.62), personal annual income (OR=1.99, 95%CI:1.38–2.88), and previous VTE history (OR=1.85, 95%CI:1.08–3.18). Conclusion The application of anti-osteoporosis drugs in elderly patients with fragility fractures is severely insufficient. Improving medication adherence and strengthening the management of fragility fracture patients are important strategies to improve anti-osteoporosis treatment.
[1] 原发性骨质疏松症诊疗指南(2022)[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(06):573-611.
[2] Cho SW, Baek S, Han S, et al. Metabolic phenotyping with computed tomography deep learning for metabolic syndrome,osteoporosis and sarcopenia predicts mortality in adults[J]. JCachexia Sarcopenia Muscle,2024,15(4):1418-1429.
[3] 黎晓妮.基于健康行为互动模式的回授法在老年髋关节置换术后髋关节功能恢复中的应用研究[D].右江民族医学院,2025.
[4] Fernández-Ávila DG, Rincón-Riaño DN, Pinzón DF, et al. Low rate of densitometric diagnosis and treatment in patients with severe osteoporosis in Colombia[J].Arch Osteoporos,2019,14(1):95.
[5] 宋咪,邱晨,邵梦琪,等.老年髋部骨折患者术后抗骨质疏松药物治疗现状及关联因素分析:一项全国多中心现况调查研究[J].解放军医学院学报,2024,45(05):469-474.
[6] 祝晓雨,张伟光,孙阿宁,等.2014—2019年我国六城市骨质疏松症患者药物治疗现状调查分析[J].临床药物治疗杂志,2021,19(08):69-75.
[7] 刘培培,温宇华,张丽亚,等.上海市普陀区中老年人群骨质疏松患病率和治疗现状横断面研究[J].同济大学学报(医学版),2021,42(01):35-41.
[8] Toh LS, Lai PS, Wu DB, et al. The development and validation of the osteoporosis prevention and awareness tool(OPAAT) in Malaysia[J].PLo S One,2015,10:e124553.
[9] 谭雅琼,罗碧华,戴如春.中文版骨质疏松认知量表的信效度[J].中华骨质疏松和骨矿盐疾病杂志,2021,14(03): 244-251.
[10] Horan M, Kim KK, Gendler P. Development and evaluation of the Osteoporosis Health Belief Scale [J].Res Nurs,1998, 21(5):155-163.
[11] 陈玉平,刘雪琴.骨质疏松症自我效能量表的信度与效度测定[J].解放军护理杂志,2005,(08):43-44.
[12] Wang PW, Li YZ, Zhuang HF, et al. Anti-osteoporosis medications associated with decreased mortality after hip fracture[J].Orthop Surg,2019,11(5):777-783.
[13] Ward KD, Klesges RC. A meta-analysis of the effects of cigaritte smoking on bone mineral density[J].Calcif Tissue Int,2001,68(5):259-270.
[14] Hiroshi Hagino, Yoko Yoshinaga, Etsuro Hamaya, et al. A real-world study of treatment patterns among patients with osteoporotic fracture:analysis of a Japanese hospital database[J].Arch Osteoporos,2023,18(1):23.
[15] Iba K, Dohke T, Takada J, et al. Improvement in the rate of inadequate pharmaceutical treatment by orthopaedic surgeons for the prevention of a second fracture over the last 10 years[J].J Orthop Sci,2018,23(1):127-131.
[16] Iba K, Takada J, Hatakeyama N, et al. Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture[J].J Orthop Sci,2006,11(5):446-449.
[17] Wang X, Li C, He Y, et al. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian,China[J].Arch Osteoporos,2020,15(1):134.
[18] Hussain M, Islam T, Islam M S, et al. Clinical insights into the role of smoking, diabetes, and rheumatoid arthritis in osteoporotic fractures[J].Arch Osteoporos,2025,20(1):87 .
[19] Ma Xinling, Xia Haiou, Wang Jinhua, et al. Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures[J].Journal of bone and mineral metabolism,2019,37(2019041700):729-729.
[20] 中共中央国务院印发《“健康中国2030”规划纲要》[EB/OL].[2025-08-20].https://www.gov.cn/zhengce/2016-10/25/content-5124174.htm.
[21] Solomon D, Gleeson T, Iversen M, et al. A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial[J]. Osteoporos Int, 2010,21 (2020090300): 137-44.
[22] 张伟,孙耀,房魏,等.上海某社区骨质疏松症患者用药依从性影响因素研究分析[J].中国农村卫生事业管理,2018, 38(12):1540-1543.
[23] Sattari M, Cauley JA, Garvan C, et al. Osteoporosis in the women’s health initiative:another treatment gap?[J].Am J Med,2017,130(8):937-948.
[24] 罗卢,熊川,罗程.骨质疏松性髋臼骨折患者术后关节功能康复的影响因素分析[J].中国现代医学杂志,2021, 31(20):42-47.
[25] 吴云,彭俊棋,张涵晴,等.2024年《国际共识声明：静脉血栓栓塞症的预防和管理（根据科学证据制定的准则）》解读[J].实用心脑肺血管病杂志,2025,33(11):1-7.